Neoadjuvant Advantages: Treating Locally Advanced Lung Cancer Neoadjuvant Advantages: Treating Locally Advanced Lung Cancer
Mark G. Kris, MD, discusses neoadjuvant therapy for patients with locally advanced lung cancers.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer
On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumors ≥4 cm or node positive) non-sm (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Keytruda (pembrolizumab) for Treatment of Patients With Resectable NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Single Agent as Adjuvant Treatment After Surgery
RAHWAY, N.J.--(BUSINESS WIRE) October 16, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda , Merck’s anti-PD-1 therapy, for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 16, 2023 Category: Drugs & Pharmacology Source Type: news
Bladder-Sparing Neoadjuvant Protocol Gets High Marks for MIBC
(MedPage Today) -- More than 40% of patients with muscle-invasive bladder cancer (MIBC) avoided immediate cystectomy after achieving a clinical complete response (cCR) with a chemoimmunotherapy combination, a prospective study showed.
Overall... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 6, 2023 Category: Hematology Source Type: news
Triple Therapy Boosts Anaplastic Thyroid Cancer Survival Triple Therapy Boosts Anaplastic Thyroid Cancer Survival
With the neoadjuvant regimen of pembrolizumab added to dabrafenib and trametinib, survival in BRAF-mutated forms of the highly aggressive cancer can go from months to more than 5 years.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 29, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Delaying Esophageal Cancer Surgery After Neoadjuvant CRT Fails in Trial
(MedPage Today) -- Prolonging the time to surgery following neoadjuvant chemoradiotherapy (CRT) for esophageal cancer failed to improve histological complete response rates and may even worsen overall survival (OS), according to results from the... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 19, 2023 Category: Gastroenterology Source Type: news
' Aspirationally Resectable'? Neoadjuvant Tx Evolves in NSCLC'Aspirationally Resectable'? Neoadjuvant Tx Evolves in NSCLC
H. Jack West, MD, and Julia Rotow, MD, discuss clinical implications of thoracic oncology research presented at ASCO 2023.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Surgical Outcomes of Perioperative Durvalumab in AEGEAN Study to be Presented at IASLC 2023 World Conference on Lung Cancer
Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented today from the phase 3 AEGEAN trial at the International Association... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 12, 2023 Category: Pharmaceuticals Tags: TRI TDS Source Type: news
S2 Episode 6: Neoadjuvant Therapy and Renal Cell Carcinoma S2 Episode 6: Neoadjuvant Therapy and Renal Cell Carcinoma
Drs Sumanta Pal and Jose A. Karam discuss neoadjuvant therapy in renal cell carcinoma, including TKIs, IO, and the need for more studies to explore the role of neoadjuvant therapy in RCC.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Episode 3: How Do You Optimize Neoadjuvant Therapy Selection? Episode 3: How Do You Optimize Neoadjuvant Therapy Selection?
Join experts Drs Kevin Kalinsky and Priyanka Sharma as they discuss their current approach to neoadjuvant therapy in triple-negative breast cancer and how the SCARLET trial might change that.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 6, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
NCI Task Force Issues Rectal Cancer Trial Design Recs NCI Task Force Issues Rectal Cancer Trial Design Recs
The consensus recommendations address key areas in rectal cancer trial design, including the need to incorporate endpoints important to patients and establish the optimal use of neoadjuvant therapy.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 16, 2023 Category: Gastroenterology Tags: Hematology-Oncology Source Type: news
For NSCLC, Neoadjuvant, Adjuvant, or Both? For NSCLC, Neoadjuvant, Adjuvant, or Both?
H. Jack West, MD, and Julia Rotow, MD, discuss data on perioperative approaches presented at ASCO 2023.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 4, 2023 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Routine Thromboprophylaxis for Advanced Ovarian Cancer? Routine Thromboprophylaxis for Advanced Ovarian Cancer?
Two thirds of venous thromboembolism events came during neoadjuvant chemotherapy and might have been prevented with direct-acting oral anticoagulants, a new study suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 24, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Sentinel Lymph Node Biopsy After Breast Cancer Chemotherapy Sentinel Lymph Node Biopsy After Breast Cancer Chemotherapy
This article reviews current evidence for the use of sentinel lymph node biopsy in breast cancer patients who received neoadjuvant chemotherapy.Chinese Clinical Oncology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - July 17, 2023 Category: Radiology Tags: Hematology-Oncology Journal Article Source Type: news
Does Timing of Surgery Affect Rectal Cancer Outcomes? Does Timing of Surgery Affect Rectal Cancer Outcomes?
Waiting more than 12 weeks for surgery following neoadjuvant therapy was associated with improved tumor regression grade and reduced risk of systemic recurrence but not overall survival.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
